Deutsche Bank Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $28

Deutsche Bank analyst David Hoang has initiated coverage on Climb Bio (NASDAQ: CLYM) with a Buy rating. The firm has set a price target of $28 for the stock.